Alan Bigman, MD
Internal Medicine · Hauppauge, NYNPI 1215975701
Payments from drug & device makers
Across 281 payments — averaging $140.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$36K
- AstraZeneca$715
- Lilly USA, LLC$530
- Novo Nordisk$445
- AbbVie$310
- Boehringer Ingelheim$201
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$31,39079%
- Travel & lodging$2,3866%
- Food & beverage$5,79215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 109 | $36,035 |
| AstraZeneca | 38 | $715 |
| Lilly USA, LLC | 27 | $530 |
| Novo Nordisk | 22 | $445 |
| AbbVie | 13 | $310 |
| Boehringer Ingelheim | 9 | $201 |
| GSK | 8 | $171 |
| Exact Sciences | 7 | $155 |
| Pfizer | 6 | $155 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $132 |
| Amgen | 5 | $104 |
| Johnson & Johnson | 4 | $102 |
| Eisai Inc. | 4 | $96 |
| Merck | 4 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Gilead | 2 | $48 |
| Viiv Healthcare Company | 2 | $47 |
| Seqirus USA Inc | 2 | $42 |
| VBI Vaccine (delaware) Inc. | 2 | $41 |
| Sanofi Pasteur Inc. | 2 | $28 |
| Global Blood Therapeutics, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Althera Pharmaceuticals LLC | 2 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$34,166
How this compares
$39,568 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $88,087 |
| VascepaIcosapent Ethyl | 123 | $71,131 |
| JardianceEmpagliflozin | 50 | $58,714 |
| MounjaroTirzepatide | 41 | $58,352 |
| JanuviaSitagliptin Phosphate | 31 | $38,998 |
| TrulicityDulaglutide | 33 | $37,710 |
| FarxigaDapagliflozin Propanediol | 31 | $37,554 |
| EliquisApixaban | 23 | $29,916 |
| EntrestoSacubitril/Valsartan | 12 | $16,586 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $8,063 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,630 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $7,005 |
| Valsartan | 83 | $3,090 |
| Icosapent Ethyl | 11 | $2,497 |
| Rosuvastatin Calcium | 128 | $2,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $530 | $96,06274 claims |
| Novo NordiskOzempic | $445 | $88,08764 claims |
| Boehringer IngelheimJardiance | $201 | $58,71450 claims |
| MerckJanuvia, Janumet | $87 | $46,00344 claims |
| AstraZenecaFarxiga | $715 | $37,55431 claims |
| PfizerEliquis | $155 | $29,91623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Hauppauge
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.